F12 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P00748 |
---|---|
Clone Names | 100427133 |
Gene ID | 2161 |
---|---|
Other Names | Coagulation factor XII, Hageman factor, HAF, Coagulation factor XIIa heavy chain, Beta-factor XIIa part 1, Beta-factor XIIa part 2, Coagulation factor XIIa light chain, F12 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | F12 |
---|---|
Function | Factor XII is a serum glycoprotein that participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then trypsin cleaves it to beta-factor XIIa. Alpha-factor XIIa activates factor XI to factor XIa. |
Cellular Location | Secreted. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes coagulation factor XII which circulatesin blood as a zymogen. This single chain zymogen is converted to atwo-chain serine protease with an heavy chain (alpha-factor XIIa)and a light chain. The heavy chain contains two fibronectin-typedomains, two epidermal growth factor (EGF)-like domains, a kringledomain and a proline-rich domain, whereas the light chain containsonly a catalytic domain. On activation, further cleavages takesplace in the heavy chain, resulting in the production ofbeta-factor XIIa light chain and the alpha-factor XIIa light chainbecomes beta-factor XIIa heavy chain. Prekallikrein is cleaved byfactor XII to form kallikrein, which then cleaves factor XII firstto alpha-factor XIIa and then to beta-factor XIIa. The activefactor XIIa participates in the initiation of blood coagulation,fibrinolysis, and the generation of bradykinin and angiotensin. Itactivates coagulation factors VII and XI. Defects in this gene donot cause any clinical symptoms and the sole effect is thatwhole-blood clotting time is prolonged.
References
Anton, A.I., et al. Ann. Hematol. 89(11):1147-1154(2010)Corral, J., et al. Blood Coagul. Fibrinolysis 21(7):632-639(2010)Romero, R., et al. Am. J. Obstet. Gynecol. 203 (4), 361 (2010) :Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Romero, R., et al. Am. J. Obstet. Gynecol. 202 (5), 431 (2010) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.